FDA approves Orbicular's generic Victoza, later sold by Cipla

The Food and Drug Administration approved a generic version of the GLP-1 drug Victoza on January 14, 2026, under abbreviated new drug application ANDA217590 ^[1]. The generic, liraglutide injection, is sponsored by Orbicular Pharmaceutical Technologies and will be sold under two labels: Orbicular's own NDC 81607-018 and Cipla USA's NDC 69097-920 ^[1].

The approved product is a 18mg/3mL (6mg/mL) subcutaneous solution, matching the strength sold in the brand-name Victoza pen ^[1]. FDA records list the therapeutic equivalence code as AP1, and the submission was reviewed on a standard, not priority, timeline ^[1]. Liraglutide belongs to the GLP-1 receptor agonist class, the same drug family as newer medicines like semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), though liraglutide itself is an older, once-daily injection rather than the once-weekly drugs that dominate the market today ^[1].

According to the source summary, these are the first liraglutide products to show up in Medicare claims data priced under $200 per claim [source summary]. That would represent a sharp drop from what brand-name Victoza has typically cost, though the sources provided do not include the exact prior Medicare price or the projected price under the new generic.

Why it matters for patients

Generic competition for liraglutide could lower out-of-pocket costs for patients who use Victoza or Saxenda-type liraglutide products, particularly those on Medicare or without robust drug coverage. A price under $200 per claim, if it holds up across pharmacies and insurance plans, would be a meaningful change from brand pricing for a GLP-1 drug, a class known for high list prices [source summary].

Liraglutide is not the same drug as semaglutide or tirzepatide, and it is dosed differently — once daily rather than once weekly. Patients currently on newer GLP-1 drugs should not assume this generic changes anything about their own prescription; it applies specifically to liraglutide-based products approved under this ANDA ^[1]. Anyone curious about whether a generic liraglutide option is relevant to their own treatment would need to ask a pharmacist or prescriber, since the sources here do not address individual treatment decisions.

The approval also signals that generic manufacturers are moving into the GLP-1 space as older brand-name patents expire, which could be an early sign of more price competition to come across this drug class, though the sources do not offer forecasts beyond this single approval.

What happens next

The FDA approval is dated January 14, 2026 ^[1]. The sources do not specify when the Orbicular and Cipla USA products will actually reach pharmacy shelves, when they will appear more broadly in insurance formularies, or how widely available the sub-$200 Medicare pricing will be. Those details are not yet known based on the available records.